Biotechnology Industry Research Assistance Council (BIRAC) is a not-for-profit Section 8, Schedule B, Public Sector Enterprise, set up by Department of Biotechnology (DBT), Government of India as an Interface Agency to strengthen and empower the emerging Biotech enterprise to undertake strategic research and innovation, addressing nationally relevant product development needs like:
USD 225 million Funding Support Provided 583 Projects Mentoring Provided 1.5 Million Sustainable Entrepreneurship and Enterprise Development (SEED)
 

BIRAC support for startups includes

BIRAC supported incubators, Bio-Biotechnology Ignition Grant Scheme, UIC-University Innovation Cluster, SPARSH, ETA Early Translation Accelerator & List of BIRAC supported companies.

Vision is to create biotechnology enterprise equipped with viable green and clean technologies for achieving bioenergy security. Vision document outlays what our long term goals should be if we are to truly achieve cost effective clean energy development with recent refinements to the technology.
 

The “Guidelines on Similar Biologic” prepared by Central Drugs Standard Control Organization (CDSCO) and the Department of Biotechnology (DBT) lay down the regulatory pathway for a Similar Biologic claiming to be Similar to an already authorized Reference Biologic.

The Department of Biotechnology (DBT), Government of India, announced the National Biotechnology Development Strategy in September 2007. Through the strategy, biotechnology was recognized as a sunrise sector that needed focussed attention. The cornerstone of the strategy was to focus on building coherence and connectivity between disciplines and bring together variegated skills across sectors to enhance synergy.
 

These Guidelines apply to all stakeholders including individual researchers, organizations, sponsors, oversight/regulatory committees and any others associated with both basic and clinical research on all types of human stem cells and their derivatives. These guidelines do not apply to research using non-human stem cells or tissues. Further, they do not regulate the use of hematopoietic stem cells for treatment of various haematological, immunological and metabolic disorders which has already been established as a standard of medical care.
 

In order to achieve the aforementioned objectives, each institution is encouraged to set up its own inter- operable institutional open access repository (“IR”) for its research papers and review articles published in peer-reviewed journals. The Ministry of Science and Technology has set up a central harvester (www.sciencecentral.in) that will harvest the full text and metadata of these publications. This central harvester will have a link to each institutional repository.
 

BIRAC is a new industry-academia interface and implements its mandate through a wide range of impact initiatives, be it providing access to risk capital through targeted funding, technology transfer, IP management and handholding schemes that help bring innovation excellence to the biotech firms and make them globally competitive. In its three years of existence, BIRAC has initiated several schemes, networks and platforms that help to bridge the existing gaps in the industry-academia Innovation research and facilitate novel, high quality affordable products development through cutting edge technologies. BIRAC has initiated partnerships with several national and global partners to collaborate and deliver the salient features of its mandate.

State government policies (BIRAC) could be accesed from the given link.